Tempest Secures Exclusive Option for Clinical-Stage In Vivo CAR-T Platform
TPST sits 26% above its 52-week low of $0.743 on elevated volume (3.4× avg).
Summary
Tempest has entered an exclusive option agreement with Senlang Biotechnology to license a CD7-targeted lentiviral in vivo CAR-T platform. The lead candidate, a BCMA/GPRC5D dual-targeting therapy, is in Phase 1 dose escalation for relapsed/refractory multiple myeloma. Early data show in vivo CAR-T generation and expansion at the highest evaluable dose, with no Grade 3+ CRS or ICANS as of August 25, 2026. This adds a second delivery platform to Tempest's existing LNP approach and expands its pipeline into hematologic malignancies and autoimmune diseases. The company remains cash-constrained, having recently raised $2.5M via private placement, so this option preserves capital while securing a clinical-stage asset. Watch for further Phase 1 data and any decision to exercise the option.
At the time of this announcement, TPST was trading at $0.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1M. The 52-week trading range was $0.74 to $12.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.